Stockreport
Regeneron's C5 Milestones And Autoimmune Bets Shape Future Valuation [Yahoo! Finance]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regeneron Pharmaceuticals (NasdaqGS:REGN) reports multiple milestones in its C5 complement program, including completion of enrollment in its pivotal paroxysmal nocturnal hemoglobinuria (PNH) study. The company announces positive phase III results for cemdisiran in generalized myasthenia gravis and submits data to the US Food and Drug Administration for review. Management is preparing for potential multi indication C5 launches, with initial approvals targeted as early as Q4 2026. Regeneron's venture arm commits new capital to early stage autoimmune programs, adding breadth to the company's future pipeline. For investors following Regeneron Pharmaceuticals (NasdaqGS:REGN), these C5 complement milestones highlight how the company is extending beyond its existing franchises into hematology and neuromuscular disease. C5 inhibition is an established target in rare immune mediated conditions, and Regeneron is positioning its program across multiple indications where complement acti
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Regeneron Pharmaceuticals (REGN) had its price target lowered by Wells Fargo & Company from $825.00 to $800.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Regeneron Tops Q1 Estimates on Dupixent Momentum [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance][Yahoo! Finance]
- Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 [Yahoo! Finance][Yahoo! Finance]
- Regeneron Reports First Quarter 2026 Financial and Operating Results [Yahoo! Finance][Yahoo! Finance]
- More
REGN
SEC Filings
SEC Filings
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- 4/24/26 - Form ARS
- REGN's page on the SEC website
- More